VACCINI | MRNA-1273 | MODERNA
- New England Journal of Medicine, 6 aprile 2021 | ” Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19″
- New England Journal of Medicine, 17 marzo 2021 | “Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine”
- New England Journal of Medicine, 17 febbraio 2021 | “Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine — Preliminary Report”
- Jama, 12 febbraio 2021 | “Reports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US—December 14, 2020-January 18, 2021”
- MMWR, 22 gennaio 2021 | “Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Moderna COVID-19 Vaccine — United States, December 21, 2020–January 10, 2021”
- AIFA, 7 gennaio 2021 | “COVID-19: AIFA autorizza vaccino Moderna”
- New England Journal of Medicine , 30 dicembre 2020 | “Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine”
- FDA, 18 dicembre 2020 | “FDA Takes Additional Action in Fight Against COVID-19 By Issuing Emergency Use Authorization for Second COVID-19 Vaccine”
- New England Journal of Medicine, 3 dicembre 2020 | “Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination”
- New England Journal of Medicine, 29 settembre 2020 | “Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults”
- JAMA , 3 settembre 2020 | “ COVID-19 and mRNA Vaccines—First Large Test for a New Approach”
- New England Journal of Medicine, 28 luglio 2020 | “ Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates”
- New England Journal of Medicine, 14 luglio 2020 | “An mRNA Vaccine against SARS-CoV-2 — Preliminary Report”
- New England Journal of Medicine, 14 luglio 2020 (editoriale) | “ The Covid-19 Vaccine-Development Multiverse”